Home › NDC Lookup › RxCUI directory › RxCUI 1005924

Ulipristal acetate 30 MG Oral Tablet — RxCUI 1005924

RxNorm drug concept · Semantic clinical drug
RxCUI 1005924 Semantic clinical drug · SCD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1005924
Official nameUlipristal acetate 30 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped2
Package NDCs mapped2
Reported Medicaid activity (SDUD)93,222 prescriptions · 44 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Ulipristal: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Take it as soon as possible — the sooner, the better. Ella is effective up to 5 days (120 hours) after unprotected sex or contraceptive failure, but it works best the earlier you t...
  • How quickly do I need to take ella after unprotected sex?
  • Some people do feel some side effects after taking ella. The most common ones are headache, nausea, abdominal pain, fatigue, and dizziness. Most of these are mild and temporary. On...
  • Will ella make me feel sick or cause any side effects?
📖 Read our full Ulipristal guide →

🕸️ Concept Web — How Ulipristal acetate 30 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Ulipristal acetate 30 MG Oral Tablet RxCUI 1005924

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Ulipristal 1005921
    • Ulipristal acetate 1005920
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Ella 1005925
  3. Dose forms 13

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Ulipristal Oral Tablet 1005923
    • Ulipristal acetate Oral Tablet 2645807
    • Ulipristal Oral Product 1163979
    • Ulipristal Pill 1163980
    • Ulipristal acetate Oral Product 2660205
    • Ulipristal acetate Pill 2659249
    • Ulipristal Oral Tablet [Ella] 1005927
    • Ulipristal acetate Oral Tablet [Ella] 2654377
    • +5 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Ulipristal acetate 30 MG SCDC · 1005922
  • Ulipristal Oral Tablet SCDF · 1005923
  • Ulipristal acetate Oral Tablet SCDFP · 2645807
  • Ulipristal Oral Product SCDG · 1163979
  • Ulipristal Pill SCDG · 1163980
  • Ulipristal acetate Oral Product SCDGP · 2660205
  • Ulipristal acetate Pill SCDGP · 2659249

Brand-Name Concepts

  • Ulipristal acetate 30 MG Oral Tablet [Ella] SBD · 1005928
  • Ulipristal acetate 30 MG [Ella] SBDC · 1005926
  • Ulipristal Oral Tablet [Ella] SBDF · 1005927
  • Ulipristal acetate Oral Tablet [Ella] SBDFP · 2654377
  • Ella Oral Product SBDG · 1174612
  • Ella Pill SBDG · 1174613
  • Ella BN · 1005925

📦 FDA Products & Package NDCs

2 products · 2 package NDCs
2 package NDCs map to RxCUI 1005924 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
50090-5422-00 1 BLISTER PACK in 1 CARTON (50090-5422-0) / 1 TABLET in 1 B... Ella A-S Medication Solutions 2021-01-06
73302-0456-01 1 BLISTER PACK in 1 CARTON (73302-456-01) / 1 TABLET in 1 B... Ella HRA PHARMA AMERICA, INC. 2020-05-11
Observed labelers: A-S Medication Solutions (1) · HRA PHARMA AMERICA, INC. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$37.0944
Range $37.0944–$37.0944 · middle 50% $37.0944–$37.0944 · 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.